[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.200.4. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
February 12, 1996

Rhinocerebral Mucormycosis: Therapy With Amphotericin B Lipid Complex

Author Affiliations

From the Departments of Surgery (Dr Kennedy), Medicine (Dr Adam), and Microbiology/Immunology (Dr Adam), University of Arizona College of Medicine, Tucson. Dr Strasser was a medical student at University of Arizona College of Medicine and is now a surgery resident (otorhinolaryngologist) at the University of Cincinnati (Ohio) College of Medicine.

Arch Intern Med. 1996;156(3):337-339. doi:10.1001/archinte.1996.00440030145018
Abstract

Rhinocerebral mucormycosis with intracranial involvement has a high mortality. The standard therapy consists of aggressive surgical débridement accompanied by high doses of amphotericin B deoxycholate. Even with this therapy, the mortality rate has been 48% in the series reported since 1980. We treated a 60-year-old diabetic woman with rhinocerebral mucormycosis involving the cavernous sinus whose infection responded to medical therapy with amphotericin B lipid complex. To our knowledge, this is the only well-documented medical cure of a patient with rhinocerebral mucormycosis and intracranial involvement.

(Arch Intern Med. 1996;156:337-339)

×